Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 6/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2050645 | 0.82 | SLC5A2 (0.47) | SLC5A2SLC5A1NOTUM | |
| SCHEMBL4854547 | 0.68 | RAB9A (0.40) | ARMEN1LMNAKMT2A | |
| SCHEMBL4860259 | 0.65 | SLC5A1 (0.47) | SLC5A2SLC5A1ARMEN1LMNA | |
| SCHEMBL13313003 | 0.64 | LMNA (0.66) | SLC5A2SLC5A1ARMEN1LMNA | |
| SCHEMBL2047194 | 0.64 | SMN1; SMN2 (0.38) | MEN1LMNAKMT2A | |
| SCHEMBL156171 | 0.63 | GPR84 (0.43) | SLC5A2SLC5A1ARMEN1LMNA | |
| SCHEMBL4230856 | 0.62 | LMNA (0.62) | ARMEN1LMNAKMT2A | |
| SCHEMBL22197860 | 0.62 | MEN1 (0.62) | ARMEN1LMNAKMT2AAPOBEC3G | |
| SCHEMBL155106 | 0.62 | ALDH1A1 (0.41) | SLC5A2SLC5A1ARMEN1LMNA | |
| SCHEMBL26100801 | 0.62 | LMNA (0.62) | ARMEN1LMNAKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439232-B2 | Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20060194809-A1 | Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1609799-A1 | HETEROARYL 5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194809-A1 | Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same | SLC5A2, SLC5A1, UGGT1 | SLC5A2 1/4885SLC5A1 2/4885AR 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.